Implantable meshes for controlling the movement of fluids
Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.
1. A wound dressing formed from woven or non-woven fibers of self-assembling peptides,
wherein the self-assembling peptides comprise a sequence of amino acid residues conforming to one or more of Formulas I-IV:
((Xaa neu −Xaa + ) x (Xaa neu −Xaa − ) y ) n (I);
((Xaa neu −Xaa − ) x (Xaa neu −Xaa + ) y ) n (II);
((Xaa + −Xaa neu ) x (Xaa − −Xaa neu ) y ) n (III);
((Xaa − −Xaa neu ) x (Xaa + −Xaa neu ) y ) n (IV);
wherein Xaa neu represents an amino acid residue having a neutral charge under physiological conditions; Xaa + represents an amino acid residue having a positive charge under physiological conditions; Xaa − represents an amino acid residue having a negative charge under physiological conditions; x and y are integers having a value of 1, 2, 3, or 4, independently; and n is an integer having a value of 1-5.
2. The wound dressing of claim 1 , wherein all of the self-assembling peptides have the same size and amino acid sequence.
3. The wound dressing of claim 1 further comprising a non-peptide material.
4. The wound dressing of claim 1 , wherein the wound dressing is partially or completely biodegradable.
5. The wound dressing of claim 1 , wherein the wound dressing further comprises one or more therapeutic, prophylactic, or diagnostic agents.
6. The wound dressing of claim 5 , wherein the one or more therapeutic, prophylactic, or diagnostic agents are selected from the group consisting of hemostatic agents, anti-infectives, growth factors, cells, anesthetics, vasoconstrictors, and a combination thereof.
7. The wound dressing of claim 1 , wherein the wound dressing forms a barrier structure that inhibits or prevents passage of bodily fluid through the structure upon contact with a bodily fluid at an exposed wound site of a subject.
8. The wound dressing of claim 1 further comprising a pH-adjusting agent.
9. The wound dressing of claim 1 , wherein the wound dressing is prepared by a method selected from the group consisting of microfluidics, injection molding, stamping, templating onto a surface having a desired shape, electrospinning, freezing of a powder, freezing of a solution, coating of a solid substrate, and combinations thereof.
10. The wound dressing of claim 9 , wherein the wound dressing is prepared by electrospinning a stock solution of the self-assembling peptides comprising a concentration of less than 5 mM Li+, Na+, K+ or Cs+ ions.
11. A method for inhibiting or preventing the movement of bodily fluids in a subject, the method comprising applying the wound dressing of claim 1 to a wound on or within the subject,
wherein the self-assembling peptides assemble to form a barrier structure that inhibits or prevents the movement of bodily fluids through the dressing.
12. The method of claim 11 , wherein the bodily fluid is blood.
13. The method of claim 11 , wherein the subject suffers from a primary, secondary, or acquired bleeding/coagulation/clotting disorder.
14. The method of claim 11 , wherein the self-assembling peptides are assembled immediately prior to, during or after application of the mesh wound dressing.
15. The method of claim 14 , wherein assembly is induced by contacting the wound dressing with a solution having a concentration of greater than 5 mM Li+, Na+, K+ or Cs+ ions.
16. The method of claim 14 , wherein assembly is induced by contacting the dressing with one or more bodily fluids present at the wound.
17. The method of claim 11 , wherein the wound is a site of traumatic injury or surgery of an organ selected from the brain, liver, stomach, intestine, skin, lung, and heart.
18. The method of claim 11 , wherein the wound is on or within a diseased or damaged tissue.
19. The method of claim 11 , wherein the wound is a burn or other wound to the skin, an ulcer, or a canker sore.
20. The method of claim 11 , wherein the wound dressing biodegrades over a period of 1 day to 8 weeks following application.
21. The wound dressing of claim 1 , wherein the wound dressing is multilayered.
22. The wound dressing of claim 21 , wherein the different layers comprise self-assembling peptides having distinct sequences or sizes.
23. The wound dressing of claim 21 , wherein the wound dressing comprises a protective, backing or support layer.
24. The wound dressing of claim 23 , wherein the protective, backing or support layer comprises an adhesive bandage, an adhesive strip, a non-adhesive, a film, a micro-porous substrate, or a sponge.
25. The wound dressing of claim 23 , wherein the protective, backing or support layer comprises poly(L-lactic acid co-ε-caprolactone) (PLCL), poly(DL-lactic acid) (PDLA), poly(lactic-co-glycolicacid) (PLGA), poly(ethylene oxide) (PEO), poly(vinyl alcohol) (PVA), poly (methyl methacrylate) (PMMA), poly(ethylene-co-vinyl acetate) (PEVA), polystyrene, polyurethane, poly(L-lactic acid) (PLLA), polylactic acid (PLA), or mixtures thereof.
26. The wound dressing of claim 1 , wherein the wound dressing is solid, semi-solid, or a gel.